Skip to content
Clinical Trials – home

Institut Catala d'Oncologia- L'Hospitalet de Llobregat

Research site

Spain Gran Via de l'Hospitalet, 08908 Barcelona, Spain

  • 2 trials recruiting
  • Essential thrombocythaemia · Squamous cell carcinoma of head and neck
  • Adult patients

About Specializations

Institut Catala d'Oncologia- L'Hospitalet de Llobregat in Barcelona, Spain specialises in clinical trials of conditions such as Essential thrombocythaemia, Squamous cell carcinoma of head and neck, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Gran Via de l'Hospitalet08908 BarcelonaSpain
Recruiting now
2 trials
Conditions studied
2

More sites in BarcelonaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

2 clinical trials

A study to evaluate the effectiveness and safety of iadademstat in adults with essential thrombocythemia who do not respond well to or cannot tolerate hydroxyurea

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Iadademstat
  • Sponsor:Oryzon Genomics S.A.

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ivonescimab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.